A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

Sponsor
Bristol-Myers Squibb
Study ID
NCT06549608
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This real-world study will describe the demographic and clinical characteristics and mavacamten treatment of adult patients with obstructive hypertrophic cardiomyopathy who participated in the Bristol-Myers Squibb (BMS)-sponsored CAMZYOS Patient Support Program in Canada.

Key Dates

Start date
Apr 20, 2024
Status verified
Jun 2026
Primary completion
May 6, 2024
Completion
Apr 18, 2025

Study Design

Enrollment
683 participants (actual)

Arms

  • Arm: Adults participants treated with mavacamten
    Participants with symptomatic obstructive hypertrophic cardiomyopathy (NYHA functional class II-III) who receive mavacamten as part of routine clinical care.

Primary Outcome Measure

Participant demographics [ Time Frame: Baseline ]

Related Studies